Investigational drug · Phase 2
sabirnetug
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "sabirnetug"
First trial start
2024
Feb 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "sabirnetug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "sabirnetug" as an intervention, largest first.
- A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)Pivotal-lookingActive, not recruiting
Acumen PharmaceuticalsIndustry
NCT06335173 · 542 participants · Start Feb 29, 2024 · Primary completion Oct 29, 2026
Drug: sabirnetug; Placebo · For: Alzheimer Disease
Sites: Carlsbad, California; Fullerton, California; Irvine, California · 68 sites in all
Acumen PharmaceuticalsIndustry
NCT06511570 · 28 participants · Start Jun 25, 2024 · Primary completion Sep 17, 2024
Drug: sabirnetug (ACU193) · For: Alzheimer Disease
Sites: San Antonio, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain.
Grenon MB, Cline EN, Jerecic J, et al. · Alzheimers Dement 2026
- Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer's disease: a qualitative interview study.
Merikle E, Presnall C, Feaster T, et al. · Trials 2026
- Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of Sabirnetug.
Moxon R, Feaster T, Sethuraman G, et al. · Alzheimers Dement (N Y) 2025
- Erratum to "Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(4): 100082].
Cline EN, Antwi-Berko D, Sundell K, et al. · J Prev Alzheimers Dis 2025
- Erratum to "INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(1): 100005.].
Siemers E, Feaster T, Sethuraman G, et al. · J Prev Alzheimers Dis 2025
- Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.
Cline EN, Antwi-Berko D, Sundell K, et al. · J Prev Alzheimers Dis 2025
Also in development for Alzheimer Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- Combined metabolic activatorsPhase 32 trials
ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease
- DMB-IINN: Latrepirdine, DimebonPhase 32 trials
Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type
- AR1001Phase 31 trial
AriBio Co., Ltd. · Alzheimer Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.